Cora Therapeutics, a life sciences start-up based in Toronto, is pleased to announce that it has raised $1 million in seed funding. This support marks the completion of the second round of seed funding, which was led by Irongate Capital Advisors of New York. Cora Therapeutics has raised $1.8 million in seed funding to date.
Cora Therapeutics, led by Dr. Kieran Murphy, is committed to providing innovative research-based solutions for whole-body health. Cora Therapeutics has created DNA HALO, a potent antioxidant formulation that protects both cellular and mitochondrial DNA from nuclear and medical radiation.
It is a patented blend of natural ingredients that complies with strict US and Canadian regulatory bodies.The formulation has been optimized in leading institutions for over a decade and currently has four issued patents worldwide.
Six clinical papers have been published in peer-reviewed journals, confirming the work that has resulted from collaborations with Dalhousie University, the University of Toronto, and McMaster University.
The funds will be used to help Cora Therapeutics launch DNA HALO in North America. They will target medical professionals, medical imaging patients, air travel professionals, frequent fliers, military personnel, and the general public who is concerned about their health.
Cora Therapeutics is committed to providing cutting-edge research-based solutions for whole-body health. It has created DNA HALO, an advanced antioxidant formulation created by physicians and backed up by extensive scientific evidence.
DNA HALO protects cells from free radical damage caused by oxidative stress.
